Results for tag: "Wet Macular Degeneration"

Wet macular degeneration, also known as neovascular or exudative macular degeneration, is a chronic eye disorder that results in the loss of central vision due to abnormal blood vessel growth under the macula, leading to leakage and scarring. The optical market has adapted to cater to the needs of individuals suffering from this condition through various products and services. Technological advancements in diagnostic imaging, suchinction as optical coherence tomography (OCT), provide detailed images of the retina, allowing for early detection and management of the disease. Furthermore, the development of anti-VEGF (vascular endothelial growth factor) medications has revolutionized the treatment of wet macular degeneration by inhibiting the growth of abnormal blood vessels in the eye. Treatment options have expanded to include photodynamic therapy and laser surgery; however, these are less common compared to anti-VEGF injections. The wet macular degeneration market also encompasses low vision aids, including specialized glasses, magnifiers, and electronic devices designed to assist those with vision impairment in their daily activities. Several companies are actively involved in the wet macular degeneration market, notable standouts being Novartis, Bayer, Roche, and Regeneron Pharmaceuticals. These companies have been instrumental in the development of therapies such as ranibizumab (Lucentis), aflibercept (Eylea), and brolucizumab (Beovu), which are widely used in the management of the disease. Show Less Read more